The 2015 Florida Legislature appropriated $1.5 million in recurring General Revenue funds to provide for extended-release injectable naltrexone (VIVITROL®)
to treat alcohol and opioid addicted in community-based treatment programs.
These funds were appropriated to the Florida Department of Children and Families and the DCF contracted with the Florida Alcohol and Drug Abuse Association (FADAA)
for the purpose of setting up a program enabling providers to access the medication.
The funds will be used to reimburse providers for VIVITROL screening, assessment, and medication administration at the following rate:
- Naltrexone Screening/Medication Education
- Naltrexone Assessment (Physical Examination, Lab Work)
- Administration of Medication (Medication Management, Medication Administration, Lab Work, and Medication)
With these dedicated resources being made available by the Legislature to access the medication, this is an opportunity for providers to expand their clinical
and medical protocols to utilize VIVITROL. FADAA has established a grant process for the selection of eligible providers and for the allocation and distribution of these funds.
If you are interested in accessing these funds to utilize VIVITROL as part of your agency's clinical protocol, please complete and submit the
following on-line application and download and submit your proposed medical protocol for the use of VIVITROL to FADAA. If you have questions,
please contact us at mat@floridabha.org or 850-878-2196.